Wedbush raised the firm’s price target on Janux Therapeutics (JANX) to $76 from $75 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company continues to enroll patients in Phase 1 studies of PSMA-targeted Tumor Activated T Cell Engager JANX007 and EGFRtargeted TRACTr JANX008, with clinical updates expected for both programs in 2025.
Education
About Us
Working with TipRanks
Follow Us
1